Recombinant Human Erythropoietin Alfa
Infarction, Middle Cerebral Artery
Max-Planck-Institute of Experimental MedicinePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Infarction, Middle Cerebral Artery cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Human Plasminogen Activator SOS Attaque Cérébrale | Phase 4 | BB |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Max-Planck-Institute of Experimental Medicine | Phase 2/3 | B |
Human Placenta-Derived Cells Pda001- Celularity Incorporated | Phase 2 | CCC |
Auto-Cd34+ Cells Imperial College London | Phase 1/2 | CCC |
Piracetam UCB S.A. - Pharma Sector | Phase 4 | CCC |
View all 10 →
Same molecule, other indications
Recombinant Human Erythropoietin Alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →